Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example
| Autor: | Vanita R. Aroda, Morten Donsmark, Trine Saugstrup, Jeppe Zacho, John B. Buse, Melanie J. Davies |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Population level Endocrinology Diabetes and Metabolism Population Glucagon-Like Peptides 030209 endocrinology & metabolism Review Article 030204 cardiovascular system & hematology Placebo Glucagon-Like Peptide-1 Receptor law.invention 03 medical and health sciences 0302 clinical medicine Endocrinology Randomized controlled trial law Internal Medicine estimand Medicine Humans education Intensive care medicine Review Articles Randomized Controlled Trials as Topic education.field_of_study Models Statistical business.industry Semaglutide GLP‐1 receptor agonists PIONEER Diabetes regulatory guidance 3. Good health Discontinuation Clinical trial Diabetes Mellitus Type 2 Estimand oral semaglutide business |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1463-1326 1462-8902 |
| Popis: | Regulatory guidelines describe the use of estimands in designing and conducting clinical trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of a trial. An estimand is defined by four inter‐related attributes: the population of interest, the variable (endpoint) of interest, the way intercurrent events are handled and the population level summary. A trial may employ multiple estimands to evaluate treatment effects from different perspectives in order to address different scientific questions. As estimands may be an unfamiliar concept for many clinicians treating diabetes, this paper reviews the estimand concept and uses the PIONEER 1 phase 3a clinical trial, which investigated the efficacy and safety of oral semaglutide vs placebo, as an example of the way in which estimands can be implemented and interpreted. In the PIONEER 1 trial, two estimands were employed for each efficacy endpoint and were labelled as: (a) the treatment policy estimand, used to assess the treatment effect regardless of use of rescue medication or discontinuation of trial product, and provides a broad perspective of the treatment effect in the population of patients with type 2 diabetes in clinical practice; and (b) the trial product estimand, used to assess the treatment effect if all patients had continued to use trial product for the planned duration of the trial without rescue medication, thereby providing information on the anticipated treatment effect of the medication. Both approaches are complementary to understanding the effect of the studied treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text